Breast cancer is now the most commonly diagnosed cancer in the world and the leading cause of cancer mortality in women worldwide.
In past few years, anti- human epidermal growth factor receptor-2 (HER2) therapy for metastatic breast cancer (mBC) has rapidly altered in China.
This study aimed to describe treatment patterns and outcomes in patients with HER2-positive unresectable or metastatic breast cancer in the real-world setting.
